Cost-effectiveness analysis of Tislelizumab vs Sorafenib as the first-line treatment of unresectable hepatocellular carcinoma
oleh: Qiuping Chen, Quan Sun, Jing Zhang, Baixue Li, Quansheng Feng, Jibin Liu
| Format: | Article |
|---|---|
| Diterbitkan: | Public Library of Science (PLoS) 2024-01-01 |
Deskripsi
No description available for this item.